July 2025 PMID 39615743

Utility of Mechanistic Target of Rapamycin Inhibitors in Cardiac Sarcoidosis.

Donald Richards, Hidesato Fujito, Aakash Shanbhag, Bobak Akhavan, Elizabeth Frame, Sean Hayes, John Friedman, Louise Thomson, Piotr Slomka, Daniel Berman, Evan P Kransdorf

Full text PDF Download social card

Mentions

Peak: 2 in Mar 2025

across 2 sources since Dec 2024

Extended reach

41,626

potential audience

Total likes

Video views

246

Mentions per month

Dec 2024 – Mar 2025

Where it's discussed

YouTube2 videos
X / Twitter1 posts

AI synopsis

What people are saying

Discussions highlight the significance of the study, with comments like 'promising new avenue' and questions about its broader applicability, reflecting genuine interest. The tone suggests students are considering the implications of using mTOR inhibitors based on the initial results, which can have meaningful impacts on treatment strategies, despite acknowledging that larger studies are needed.

AgreementModerate agreement

Many discussions acknowledge the potential of mTOR inhibitors highlighted in the publication, though some express cautious optimism rather than full agreement.

InterestModerate interest

Participants show moderate curiosity, referencing specific findings like the reduction in cardiac inflammation and debating its clinical significance.

EngagementModerate engagement

Commenters delve into details such as the small sample size and the novelty of using mTOR inhibitors, indicating active engagement.

ImpactModerate impact

Overall, there's recognition that this research could influence future treatment approaches for cardiac sarcoidosis, though it's seen as preliminary.

Abstract in brief

Cardiac sarcoidosis is a serious form of the multisystem disease sarcoidosis, typically treated with corticosteroids, but there is growing interest in steroid-sparing medications due to steroid-related complications.
Researchers evaluated the effectiveness of mTOR inhibitors in 4 patients with active cardiac sarcoidosis who couldn't intensify corticosteroid treatment, using FDG-PET imaging to measure changes in cardiac inflammation.
Results showed that 2 of the patients experienced significant reductions in cardiac inflammation after 6 months, while the other 2 still had inflammation, indicating a need for alternative treatments; this is the first clinical exploration of mTOR inhibitors for this condition.

Read the full abstract

All mentions

Sirolimus Treatment for Cutaneous Sarcoidosis by mTOR Inhibition

Dr Anna Gabriel discusses her study on Sirolimus for treating skin sarcoidosis at Vienna's AKH University Clinic, highlighting how mTOR inhibition using Sirolimus shows promise for managing resistant sarcoidosis cases.

Lungenfibrose Forum Austria · Mar 21, 2025 125 views

Targeted mTOR Inhibition with Sirolimus for Pulmonary Sarcoidosis

Dr Anna Gabriel ne Redl discusses a sirolimus trial for sarcoidosis patients, highlighting its potential to reduce inflammation and improve lung function in cases unresponsive to traditional treatments.

Lungenfibrose Forum Austria · Mar 21, 2025 122 views

Agingdoc

@agingdoc1 · X

Utility of Mechanistic Target of Rapamycin Inhibitors in Cardiac Sarcoidosis https://t.co/GfHSUbzlmx

Dec 3, 2024 · 4 likes · 41,381 followers View post →